Pargluva Rejection Urged By Public Citizen
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee's recommendation for approval of Bristol-Myers Squibb's diabetes agent was "inappropriate" because it was based on "vague promises" from industry, Public Citizen says in a letter to the agency.